Live Breaking News & Updates on Oherus biosciences

Stay informed with the latest breaking news from Oherus biosciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Oherus biosciences and stay connected to the pulse of your community

Coherus Announces Presentation at the 2024 American Society

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...

Mccormick-place , Illinois , United-states , Chicago , Jami-taylor , Jodi-sievers , Coherus-biosciences , Corporate-communications , Exchange-commission-on , Exchange-commission , Abbvie-inc , Nasdaq

Coherus BioSciences Announces New Employment Inducement

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

Jami-taylor , Coherus-biosciences-inc , Nasdaq , Executive-vice-president , Coherus-biosciences , Commencement-incentive-plan , Nasdaq-global-select-market , Nasdaq-chrs , Oherus-biosciences , Nc- ,

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety...

United-states , New-york , Coherus-biosciences , Jodi-sievers , Paul-reider , Maria-theodoulou , Jami-taylor , Kathleen-clifford , Coherus-biosciences-inc , Luke-health-system , Exchange-commission , Nasdaq

Coherus to divest ophthalmology business for $170M

"Coherus BioSciences to divest ophthalmology franchise, Cimerli, to Sandoz for $170 million. Deal includes product inventory and access to commercial software

Coherus-biosciences , Meta-keywords-biopharmaceutical , Oherus-biosciences , Ivest , Phthalmology-franchise , Andoz , 70-million , Imerli , Roduct-inventory ,

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel

– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and...

United-states , Denny-lanfear , Jami-taylor , Paul-reider , Coherus-biosciences , Coherus-biosciences-inc , Drug-administration , Exchange-commission , Nuclear-imaging , Nasdaq , Coheru-chief-commercial , Rich-hameister

FDA approves new head and neck cancer drug

FDA grants approval for toripalimab-tpzi, a new drug therapy for head and neck cancer patients.

Coherus-biosciences , Fda , Oripalimab-tpzi , Oherus-biosciences , Asopharyngeal-carcinoma , Riority-review , Reakthrough-therapy , Isplatin , Emcitabine , Latinum-containing , Herapy

Coherus and Junshi Biosciences Announce FDA Approval of

– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy...

California , United-states , China , Guangzhou , Guangdong , Massachusetts , Shanghai , Beijing , Suzhou , Jiangsu , Maryland , Chinese

Coherus BioSciences Announces New Employment Inducement

REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

Jodi-sievers , Nasdaq , Coherus-biosciences-inc , Coherus-biosciences , Commencement-incentive-plan , Nasdaq-global-select-market , Biosciences-contact-information , Nasdaq-chrs , Oherus-biosciences , Nc- ,

'Load Up,' Says Citigroup, About These 2 'Strong Buy' Stocks

As the final quarter of 2023 gets fully underway, analysts and investors alike are trying to divine just what is likely to happen in the next few months. There’s a growing feeling that, with September behind us, stock investors can look forward to better times – perhaps sooner rather than later. In some recent comments to CNBC, Scott Chronert, Citi U.S. equity strategist, gives several reasons why investors should load up on stocks now. First, Chronert points out that fears of a hard recession h

Texas , United-states , America , Coherus-biosciences , Scott-chronert , Yigal-nochomovitz , Citi-scott-gruber , Udenyca-neulasta , Citigroup , Strong-buy , Surface-oncology , West-texas

Coherus BioSciences: FDA Issues CRL For UDENYCA ONBODY Biologics License Application

Coherus BioSciences, Inc. (CHRS) said the FDA issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA, solely due to an ongoing review of inspection findings at a third-party filler.

China , Coherus-biosciences , More-such-health-news , Coherus-biosciences-inc , Complete-response-letter , Biologics-license-application , Fda , Oherus-biosciences ,